European urology最新文献

{"title":"Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052","authors":"Giuseppe Di Lorenzo, Massimo Di Maio","doi":"10.1016/j.eururo.2026.06.014","DOIUrl":"10.1016/j.eururo.2026.06.014","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages e91-e92"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148371507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol 2026;89:550–551","authors":"Neal D. Shore, Stephen J. Freedland","doi":"10.1016/j.eururo.2026.04.032","DOIUrl":"10.1016/j.eururo.2026.04.032","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages 434-435"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148427585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9 yr Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial","authors":"Roman Gulati,Ruth Etzioni","doi":"10.1016/j.eururo.2026.09.015","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.09.015","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"38 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149092032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Riccardo Lombardo’s Letter to the Editor re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.06.020","authors":"Bi-Ming He,Hai-Feng Wang","doi":"10.1016/j.eururo.2026.09.018","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.09.018","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"24 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Tikkinen KAO, Najafabadi BT, Hajebrahimi S, et al. A Multicenter Randomized Controlled Trial of Antimicrobial Prophylaxis to Prevent Urinary Tract Infections after Shockwave Lithotripsy for Urolithiasis: The APPEAL Trial. Eur Urol 2025;88(6):543–51","authors":"Maxime Vallée, Fabian Peter Stangl, Florian Wagenlehner, Zafer Tandogdu, Jennifer Kranz, Gernot Bonkat","doi":"10.1016/j.eururo.2026.03.038","DOIUrl":"10.1016/j.eururo.2026.03.038","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages e87-e88"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147984916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European Association of Urology Guidelines on Urological Infections: Summary of the 2026 Guidelines","authors":"Jennifer Kranz,&nbsp;Tommaso Cai,&nbsp;Suzanne Geerlings,&nbsp;Bela Köves,&nbsp;Merel M.C. Lambregts,&nbsp;Guglielmo Mantica,&nbsp;Adrian Pilatz,&nbsp;Jose Medina-Polo,&nbsp;Laila Schneidewind,&nbsp;Sören Schubert,&nbsp;Maxime Vallée,&nbsp;Rajan Veeratterapillay,&nbsp;Florian Wagenlehner,&nbsp;Kathrin Bausch,&nbsp;Wout Devlies,&nbsp;Lorenz Leitner,&nbsp;Fabian Stangl,&nbsp;Hala Ali,&nbsp;Emma J. Smith,&nbsp;Gernot Bonkat","doi":"10.1016/j.eururo.2026.04.011","DOIUrl":"10.1016/j.eururo.2026.04.011","url":null,"abstract":"<div><h3>Background and objective</h3><div>Urological infections significantly impact individuals’ well-being and quality of life due to their widespread occurrence and diverse clinical manifestations. This work aims to provide evidence-based guidance on diagnosing, treating, and preventing urinary tract infections (UTIs) and male accessory gland infections, while addressing crucial public health aspects related to infection control and antimicrobial stewardship.</div></div><div><h3>Methods</h3><div>For the 2026 Urological Infections Guidelines, new and relevant evidence was identified, collated, and appraised through a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Library. Recommendations within the Guidelines were developed by the panels to prioritise clinically important care decisions. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and the nature and variability of patient values and preferences.</div></div><div><h3>Key findings and limitations</h3><div>Key recommendations emphasise the importance of thorough medical history and physical examination for patients with urological infections. The guidelines stress the role of antimicrobial stewardship to combat the rising threat of antimicrobial resistance, providing recommendations for antibiotic selection, dosing, and duration based on the latest evidence. Key updates in the 2026 Urological Infections Guidelines summary include: comprehensive restructuring of the guideline framework in alignment with the new classification system for UTIs; the addition of a new chapter on the diagnosis and management of Herpes simplex virus; the addition of a new chapter on the diagnosis and treatment of fungal UTIs; and an update of the evidence and recommendations on periprocedural antibiotic prophylaxis for prostate biopsy.</div></div><div><h3>Conclusions and clinical implications</h3><div>This overview of the 2026 European Association of Urology (EAU) guidelines offers valuable insights into the classification, diagnosis, and treatment of urological infections and is designed to be effectively integrated into clinical practice.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages 413-429"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148458221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Bladder Cancer","authors":"Veronica Mollica,Matteo Rosellini,Matteo Santoni,Francesco Massari","doi":"10.1016/j.eururo.2026.09.014","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.09.014","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"166 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “B7-H3 as a Therapeutic Target in Advanced Prostate Cancer” [European Urology 83 (2023) 224–238","authors":"Christina Guo,&nbsp;Ines Figueiredo,&nbsp;Bora Gurel,&nbsp;Antje Neeb,&nbsp;George Seed,&nbsp;Mateus Crespo,&nbsp;Suzanne Carreira,&nbsp;Jan Rekowski,&nbsp;Lorenzo Buroni,&nbsp;Jon Welti,&nbsp;Denisa Bogdan,&nbsp;Lewis Gallagher,&nbsp;Adam Sharp,&nbsp;Maria D. Fenor de la Maza,&nbsp;Pasquale Rescigno,&nbsp;Daniel Westaby,&nbsp;Khobe Chandran,&nbsp;Ruth Riisnaes,&nbsp;Ana Ferreira,&nbsp;Susana Miranda,&nbsp;Johann S. de Bono","doi":"10.1016/j.eururo.2026.07.031","DOIUrl":"10.1016/j.eururo.2026.07.031","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages 442-443"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) – A Summary of the 2026 Guidelines Update","authors":"Paolo Gontero,&nbsp;Paramananthan Mariappan,&nbsp;Benjamin Pradere,&nbsp;Bhavan P. Rai,&nbsp;Fredrik Liedberg,&nbsp;Eva Compérat,&nbsp;Jeremy Yuen-Chun Teoh,&nbsp;Marco Moschini,&nbsp;Francesco Soria,&nbsp;Bas W.G. van Rhijn,&nbsp;Joyce Baard,&nbsp;Alison Birtle,&nbsp;Maresa Botha,&nbsp;Otakar Capoun,&nbsp;David D’Andrea,&nbsp;Edoardo Fiorini,&nbsp;Alexandra Masson-Lecomte,&nbsp;Thomas Seisen,&nbsp;Shahrokh F. Shariat,&nbsp;Emma J. Smith,&nbsp;José L. Dominguez-Escrig","doi":"10.1016/j.eururo.2026.04.009","DOIUrl":"10.1016/j.eururo.2026.04.009","url":null,"abstract":"<div><h3>Background and objective</h3><div>This publication represents a summary of the updated 2026 European Association of Urology (EAU) Guidelines for nonmuscle-invasive bladder cancer (NMIBC), TaT1 and carcinoma <em>in situ</em> (CIS). The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC, with a focus on clinical presentation.</div></div><div><h3>Methods</h3><div>For the 2026 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included MEDLINE, EMBASE, and the Cochrane Library. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences.</div></div><div><h3>Key findings and limitations</h3><div>Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients’ risk stratification and treating them appropriately. Key updates in the 2026 NMIBC Guidelines summary include: the addition of two new tables addressing risk factors for bladder cancer and prognostic factors for progression in subtypes; the addition of two new tables summarising the treatment options for Bacillus Calmette–Guérin (BCG)-unresponsive tumours; inclusion of a new section addressing the addition of immune checkpoint inhibitors to BCG in selected high- and very high-risk NMIBC BCG-NAÏVE patients; a new table addressing the role of urinary markers in follow-up; and the addition of a new section on pragmatic de-intensification strategy for NMIBC.</div></div><div><h3>Conclusions and clinical implications</h3><div>This overview of the 2026 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. They are designed for effective integration into clinical practice.</div></div><div><h3>Patient summary</h3><div>The EAU has issued updated clinical practice guidelines on NMIBC. The guidelines provide recommendations for diagnosis, treatment, and follow-up, with a particular focus on quality of life for patients.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages 389-412"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148458197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA-PET/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial","authors":"Colin Belliveau,Fred Saad,Danny Duplan,Claire Petit,Guila Delouya,Carole Lambert,Daniel Taussky,Maroie Barkati,Marie-Claude Beauchemin,Sebastien Clavel,Gary Mok,Anne-Sophie Gauthier-Paré,Levon Igidbashian,Marjory Jolicoeur,Thu-Van Nguyen,Pierre-Yves McLaughlin,Philip Wong,Khun Visith Keu,Jean N. DaSilva,Daniel Juneau,Cynthia Ménard","doi":"10.1016/j.eururo.2026.09.017","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.09.017","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"151 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}